Survey of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Switzerland

Sauteur, Patrick M. Meyer; Bleisch, Barbara; Voit, Antje; Maurer, Florian P.; Relly, Christa; Berger, Christoph; Nadal, David; Bloemberg, Guido V.

doi:10.4414/smw.2014.14041

Cited by 17 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As expected an increase in molecular detection of infection is noted, with declining use of culture. Macrolide resistance has recently been documented at 9.3% found in adult patients only (Brown et al, 2015a ) and is also of concern in children in other countries (Meyer Sauteur et al, 2014a ). However, this was derived from results of specimens submitted to the reference laboratory which may be biased toward those developing resistance during treatment and one patient was documented to have received macrolides prior to sampling therefore this level may be an over-representation to the actual level in the community.…”

Section: Discussionmentioning

confidence: 99%

“…The recent global increase in macrolide resistance observed in cases of M. pneumoniae infection is of increasing concern and importance to the international community (Bébéar, 2012 ). In China resistance has been documents in over 90% of clinical isolates of M. pneumoniae studied (Zhao et al, 2013 ) however resistance is lower in European counties including France, Germany, Switzerland, and Sweden (Peuchant et al, 2009 ; Meyer Sauteur et al, 2014a ; Nilsson et al, 2014 ; Dumke et al, 2015 ). Macrolides are currently recommended as the first-line treatment for M. pneumoniae infection in the UK (Harris et al, 2011 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mycoplasma pneumoniae Epidemiology in England and Wales: A National Perspective

et al. 2016

View full text Add to dashboard Cite

Investigations of patients with suspected Mycoplasma pneumoniae infection have been undertaken in England since the early 1970s. M. pneumoniae is a respiratory pathogen that is a common cause of pneumonia and may cause serious sequelae such as encephalitis and has been documented in children with persistent cough. The pathogen is found in all age groups, with higher prevalence in children aged 5–14 years. In England, recurrent epidemic periods have occurred at ~4-yearly intervals. In addition, low-level sporadic infection occurs with seasonal peaks from December to February. Voluntarily reports from regional laboratories and hospitals in England from 1975 to 2015 were collated by Public Health England for epidemiological analysis. Further data pertaining cases of note and specimens submitted to Public Health England from 2005 to 2015 for confirmation, molecular typing is included.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Mycoplasma pneumoniae Epidemiology in England and Wales: A National Perspective

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Since 2000, the emergence of macrolide-resistant M. pneumoniae strains has become a growing global problem. Macrolide resistance rates were reported to be approximately 3% in Germany [8], 10% in France [9], 2% in Switzerland [10], 26% in Italy [11], 3% in Denmark [12], and 11% in the United States [13]. Finally in Spain, the presence of a macrolide-resistant M. pneumoniae isolate causing community-acquired pneumonia was first reported in 2014 [14].…”

Section: Introductionmentioning

confidence: 99%

Antimicrobial susceptibility and genotyping of Mycoplasma pneumoniae isolates in Beijing, China, from 2014 to 2016

Zhao

Liu

Shi

et al. 2019

Antimicrob Resist Infect Control

View full text Add to dashboard Cite

BackgroundThe presence of macrolide-resistant Myocplasma pneumoniae has been frequently reported in recent years, especially in China. In this study, we investigated the antimicrobial susceptibility and genotype against M. pneumoniae isolates from 2014 to 2016, Beijing.MethodsWe investigated the activities of four antibiotics against 81 M. pneumoniae isolates in vitro. All isolates were amplification of domains II and V of the 23S rRNA gene and the L4 and L22 ribosomal protein fragments. All isolates were genotyped with duplex real-time PCR, MLVA and VNTR detection in p1 gene.ResultsThe macrolide resistance rate was 65.4% (53/81). Each of the macrolide-resistant M. pneumoniae isolates was resistant to erythromycin (Minimum Inhibitory Concentration, MIC, ≥256 μg/ml) and azithromycin (MIC, 2–64 μg/ml), but susceptible to tetracycline and levofloxacin in vitro. Fifty two macrolide-resistant isolates harbored the A2063G mutation, and only 1 macrolide-resistant isolates harbored the A2064G mutation in domain V of the 23S ribosomal RNA gene. The C162A, A430G, and T279C mutations in the L4 and L22 ribosomal protein genes were not responsible for macrolide resistance, but they were related to the particular genotype of M. pneumoniae. 95.7% of type 1 isolates (45/47) were macrolide-resistance, and 23.5% of the type 2 isolates (8/34) were macrolide-resistance. Type 2 M. pneumoniae macrolide-resistance rate was 50.6% higher than that of the previous reports in China. The eight macrolide-resistant type 2 M. pneumoniae isolates were belong to 3/5/6/2 and 3/5/7/2 MLVA genotypes.ConclusionTo our knowledge, this phenomenon likely resulted from a combination of genotype shifting from type1 to type 2 and antibiotic selection pressure in M. pneumoniae in China in recent years. The increase of resistance in type 2 is not due to the spread of same clone. However, the relationship between genotype shifts and macrolide resistance in M. pneumoniae needs to be further verified with more extensive surveillance data.

show abstract

“…While sporadic infections are common, outbreaks of M. pneumoniae- induced disease occur in schools, child-care facilities, inpatient institutions and military barracks [3]. Azithromycin and other macrolides are used for the treatment of infections caused by M. pneumoniae [4], but an increase in the frequency of reports of macrolide resistance, particularly in Europe, Asia and North America, is of major concern [5,6,7,8,9,10,11,12,13,14,15,16,17,18,19]. Efficacious vaccines for the prevention of infections caused by M. pneumoniae are yet to be developed and are complicated by the presence of antigens that are capable of evoking an autoimmune response [20].…”

Section: Introductionmentioning

confidence: 99%

P40 and P90 from Mpn142 are Targets of Multiple Processing Events on the Surface of Mycoplasma pneumoniae

et al. 2015

View full text Add to dashboard Cite

Mycoplasma pneumoniae is a significant cause of community acquired pneumonia globally. Despite having a genome less than 1 Mb in size, M. pneumoniae presents a structurally sophisticated attachment organelle that (i) provides cell polarity, (ii) directs adherence to receptors presented on respiratory epithelium, and (iii) plays a major role in cell motility. The major adhesins, P1 (Mpn141) and P30 (Mpn453), are localised to the tip of the attachment organelle by the surface accessible cleavage fragments P90 and P40 derived from Mpn142. Two events play a defining role in the formation of P90 and P40; removal of a leader peptide at position 26 (23SLA↓NTY28) during secretion to the cell surface and cleavage at amino acid 455 (452GPL↓RAG457) generating P40 and P90. Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) analysis of tryptic peptides generated by digesting size-fractionated cell lysates of M. pneumoniae identified 15 cleavage fragments of Mpn142 ranging in mass from 9–84 kDa. Further evidence for the existence of cleavage fragments of Mpn142 was generated by mapping tryptic peptides to proteins recovered from size fractionated eluents from affinity columns loaded with heparin, fibronectin, fetuin, actin, plasminogen and A549 surface proteins as bait. To define the sites of cleavage in Mpn142, neo-N-termini in cell lysates of M. pneumoniae were dimethyl-labelled and characterised by LC-MS/MS. Our data suggests that Mpn142 is cleaved to generate adhesins that are auxiliary to P1 and P30.

show abstract

Survey of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Switzerland

Cited by 17 publications

References 13 publications

Mycoplasma pneumoniae Epidemiology in England and Wales: A National Perspective

Mycoplasma pneumoniae Epidemiology in England and Wales: A National Perspective

Antimicrobial susceptibility and genotyping of Mycoplasma pneumoniae isolates in Beijing, China, from 2014 to 2016

P40 and P90 from Mpn142 are Targets of Multiple Processing Events on the Surface of Mycoplasma pneumoniae

Contact Info

Product

Resources

About